Skip to content

TransMedics

US · TMDX #2536 by market cap Listed 2019
85.25 -8.77 -9.33%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Valuation each multiple against its own 5-year range

P/B ratio 5.76 Cheap vs history 10th percentile
5-year average 14.27 · #97 of 126 in Medical Devices
P/E ratio 24.90 Expensive vs history 67th percentile
5-year average 159.86 · forward 32.53 · #18 of 39 in Medical Devices
P/S ratio 4.36 Cheap vs history 8th percentile
5-year average 13.94 · forward 3.69 · #96 of 136 in Medical Devices

Vs. peers Medical Devices

Company Market cap P/E (TTM) P/B Div yield
TransMedics (TMDX) 2.96B 23.23 5.38 0.00%
Abbott Laboratories (ABT) 178.39B 38.29 3.50 2.41%
Medtronic (MDT) 127.84B 24.62 2.54 2.85%
Stryker Corp (SYK) 118.01B 33.01 5.03 1.14%
Boston Scientific (BSX) 60.85B 17.71 2.37 0.00%
Edwards Lifesciences (EW) 58.56B 57.54 5.39 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value100.40 Economic moatNone UncertaintyHigh

Trading 17.8% below Morningstar's fair value estimate.

Fair value

TransMedics Group Inc receives a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 9% discount to our quantitative fair value estimate of $100.40 per share; however, caution is warranted due to this estimate's high uncertainty rating.

The firm's solid growth bolsters our estimated valuation. Consistent revenue and earnings growth indicates a company's potential for increased market share and profitability. For example, the firm's revenue 3-year growth of 52.3% lies in the top 10% globally. Robust trailing three-year revenue growth portends a favorable future trajectory, which contributes to our view that shares are cheap.

On a different note, the company's valuation metrics are potentially concerning. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's book value yield of 18.0%, a core component of valuation, lies in the bottom 20% compared with global peers. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which, despite our favorable price/fair value ratio, is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has been a laggard relative to the broader universe over the past year. This underperformance makes the stock appear cheap, which portends a buying opportunity in light of other contributors to our model.

Economic moat

This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 20:02:23 · For reference only, not investment advice and not tailored to your situation.

TransMedics discussion 0 comments

Add a comment